Retrobulbar optic neuritis after pamidronate administration in a patient with a history of cutaneous porphyria.
We describe the case of a patient who developed reversible retrobulbar optic neuritis after intravenous pamidronate therapy for established osteoporosis. This possible complication has never been previously reported and, since our patient had a history of porphyria, it suggests that bisphosphonates should be administered cautiously in patients with this disease.
des Grottes
J M
JM
Service de Médecine, Institut Jules Bordet, Brussels, Belgium.
Schrooyen
M
M
Dumon
J C
JC
Body
J J
JJ
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D005074:Evoked Potentials, Visual; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D009902:Optic Neuritis / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy*; D000077268:Pamidronate; D011164:Porphyrias / Q000150:complications; D011239:Prednisolone / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D004164:Diphosphonates; D011239:Prednisolone; D000077268:Pamidronate